Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advisory Panel For Bristol's Yervoy Is Called Off, Which May Bode Well

This article was originally published in The Pink Sheet Daily

Executive Summary

After extending the review, FDA says it no longer needs ODAC's advice on the second-line melanoma treatment, which looks like a good sign for approval.
Advertisement

Related Content

Yervoy Cuts To The Head Of The Line: Ipilimumab Has Unrestricted Label
Yervoy Cuts To The Head Of The Line: Ipilimumab Has Unrestricted Label
Plexxikon, Roche Near Catalyst For BRAF Inhibitor In Melanoma
Plexxikon, Roche Near Catalyst For BRAF Inhibitor In Melanoma
Bristol's Yervoy Gets A Bigger Advisory Committee Cushion
Bristol's Yervoy Gets A Bigger Advisory Committee Cushion
Regulatory And Policy News, In Brief
FDA Says Lux's Uveitis Treatment Luveniq Needs Another Clinical Trial
Last-Minute Cancellation Of Advisory Panel Meeting Throws Future of Luveniq Into Doubt
Increased Advisory Cmte. Preparation Ahead May Challenge FDA, Sponsors

Topics

Advertisement
UsernamePublicRestriction

Register

PS071653

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel